Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

121. Use of fMRI in the presurgical evaluation of patients with epilepsy

Use of fMRI in the presurgical evaluation of patients with epilepsy Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share January 24, 2017 ; 88 (4) Special Article Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy Report (...) Health & Science University, Portland; Department of Neurology (J.A.F.), New York University, New York; and Clinical Epilepsy Section (W.H.T.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD. David Gloss From the Department of Neurology (J.P.S.), University of Alabama at Birmingham; Department of Neurology (D.G.), Charleston Area Medical Center, WV; Department of Neurology (J.R.B., S.J.S.), Medical College of Wisconsin, Milwaukee; Children's National Medical Center (W.D.G

2017 American Academy of Neurology

122. Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. (PubMed)

Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. This is an updated version of the original Cochrane Review, first published in Issue 1, 2003 and updated in 2015. This review is one in a series of Cochrane Reviews investigating pair-wise monotherapy comparisons.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment (...) , up to 70% of individuals with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.Worldwide, carbamazepine and phenobarbitone are commonly used broad-spectrum antiepileptic drugs, suitable for most epileptic seizure types. Carbamazepine is a current first-line treatment for partial onset seizures, and is used in the USA and Europe. Phenobarbitone is no longer considered

Full Text available with Trip Pro

2016 Cochrane

123. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. (PubMed)

Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Carbamazepine (CBZ) is a commonly used drug for epilepsy that is associated with troublesome adverse events including dizziness, double vision, drowsiness, poor co-ordination and unsteadiness. These adverse events often occur during peaks in drug plasma concentration. These adverse events may limit the daily dose of CBZ that can be tolerated and reduce the chances of seizure control in patients who require (...) review questions were investigated.(1) For newly diagnosed patients commencing CBZ, how do IR and CR formulations compare for efficacy and tolerability?(2) For patients on established treatment with IR CBZ but experiencing unacceptable adverse events, what is the effect on seizure control and the tolerability of a switch to a CR formulation versus remaining on the IR formulation?We searched the Cochrane Epilepsy Group Specialized Register, CENTRAL, and MEDLINE (Ovid) from inception to 30 August 2016

2016 Cochrane

124. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. (PubMed)

Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy, the majority of which may be able to achieve remission (...) a synthesis of the evidence from existing trials will increase the precision of results of outcomes relating to efficacy and tolerability, and may help inform a choice between the two drugs.To assess the effects of topiramate monotherapy versus carbamazepine monotherapy for epilepsy in people with partial-onset seizures (simple or complex partial and secondarily generalised) or generalised onset tonic-clonic seizures (with or without other generalised seizure types).We searched the Cochrane Epilepsy Group

Full Text available with Trip Pro

2016 Cochrane

125. Cannabinoids for refractory epilepsy treatment

Cannabinoids for refractory epilepsy treatment Cannabinoids for refractory epilepsy treatment Cannabinoids for refractory epilepsy treatment Soto N, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, Pichon-Riviere A, Augustovski F (...) , García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Cannabinoids for refractory epilepsy treatment. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 499. 2016 Authors' conclusions There is scarce and low quality evidence on cannabinoids (specifically cannabidiol) potential in reducing the frequency of seizures in patients with refractory epilepsy. The Clinical Practice Guidelines and health sponsors consulted do

2016 Health Technology Assessment (HTA) Database.

126. Relationship between Bone Density and Biochemical Markers of Bone among Two Groups Taking Carbamazepine and Sodium Valproate for Epilepsy in Comparison with Healthy Individuals in Yazd (PubMed)

Relationship between Bone Density and Biochemical Markers of Bone among Two Groups Taking Carbamazepine and Sodium Valproate for Epilepsy in Comparison with Healthy Individuals in Yazd Chronic antiepileptic therapy has been associated with metabolic bone diseases including osteomalacia and osteoporosis. The aim of this study was to determine frequency of changes in biochemical and bone mineral density (BMD) in adults receiving valproaic acid (VPA) & carbamazepine (CBZ).In a cross sectional (...) supplement could be considered for all patients with epilepsy upon initiation of CBZ and VPA therapy.

Full Text available with Trip Pro

2016 Electronic physician

127. WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy. (PubMed)

WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy. Most people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic drug, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy.To evaluate the effects of oxcarbazepine when used as an add (...) -on treatment for drug-resistant partial epilepsy.We searched the Cochrane Epilepsy Group's Specialized Register (28 March 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (1966 to March 2006). No language restrictions were imposed. We checked the reference lists of retrieved studies for additional reports of relevant studies. We also contacted Novartis (manufacturers of oxcarbazepine) and experts in the field.Randomized, placebo-controlled

Full Text available with Trip Pro

2016 Cochrane

128. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. (PubMed)

Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. This is an updated version of the original Cochrane review published in Issue 1, 2006 of the Cochrane Database of Systematic Reviews.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become seizure (...) seizure with lamotrigine compared to carbamazepine when used as monotherapy in people with partial onset seizures (simple or complex partial and secondarily generalised) or generalised onset tonic-clonic seizures (with or without other generalised seizure types).The first searches for this review were run in 1997. For the most recent update we searched the Cochrane Epilepsy Group Specialized Register (17 October 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane

2016 Cochrane

129. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. (PubMed)

Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. There is evidence that certain antiepileptic drugs (AEDs) are teratogenic and are associated with an increased risk of congenital malformation. The majority of women with epilepsy continue taking AEDs throughout pregnancy; therefore it is important that comprehensive information on the potential risks associated with AED treatment is available.To assess the effects of prenatal exposure to AEDs (...) on the prevalence of congenital malformations in the child.We searched the Cochrane Epilepsy Group Specialized Register (September 2015), Cochrane Central Register of Controlled Trials (CENTRAL) (2015, Issue 11), MEDLINE (via Ovid) (1946 to September 2015), EMBASE (1974 to September 2015), Pharmline (1978 to September 2015), Reprotox (1983 to September 2015) and conference abstracts (2010-2015) without language restriction.We included prospective cohort controlled studies, cohort studies set within pregnancy

Full Text available with Trip Pro

2016 Cochrane

130. Treatment of epilepsy for people with Alzheimer's disease. (PubMed)

Treatment of epilepsy for people with Alzheimer's disease. Any type of seizure can be observed in Alzheimer's disease (AD). Antiepileptic drugs seem to prevent the recurrence of epileptic seizures in most people with AD. There are pharmacological and non-pharmacological treatments for epilepsy in people with AD. There are no current systematic reviews to evaluate the efficacy and tolerability of the treatment. This review aims to review those different modalities.To assess the efficacy (...) and tolerability of the treatment of epilepsy for people with Alzheimer's disease (AD) (including sporadic AD and dominantly inherited AD).We searched the Cochrane Epilepsy Group Specialized Register (1 February 2016), the Cochrane Central Register of Controlled Trials (1 February 2016), MEDLINE (Ovid, 1 February 2016) and ClinicalTrials.gov (1 February 2016). In an effort to identify further published, unpublished and ongoing trials, we searched ongoing trials' registers, reference lists and relevant

Full Text available with Trip Pro

2016 Cochrane

131. Sialanar (glycopyrronium) - for treating severe drooling of saliva in children and adolescents (aged 3 years and above) with conditions affecting the nervous system, such as cerebral palsy, epilepsy and neurodegenerative diseases

Sialanar (glycopyrronium) - for treating severe drooling of saliva in children and adolescents (aged 3 years and above) with conditions affecting the nervous system, such as cerebral palsy, epilepsy and neurodegenerative diseases 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 21 July 2016 EMA/555265/2016 Committee

2016 European Medicines Agency - EPARs

132. Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial (PubMed)

Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial To investigate whether mammalian target of rapamycin complex 1 (mTORC1) inhibitors could reduce seizure frequency in children with tuberous sclerosis complex (TSC).Due to slow inclusion rate, target inclusion of 30 children was not reached. Twenty-three children with TSC and intractable epilepsy (age 1.8-10.9 years) were randomly assigned (1:1) to open-label, add-on sirolimus treatment immediately (...) to investigate if patients with TSC with seizures benefit from mTORC1 inhibition. This trial was registered at trialregister.nl (NTR3178) and supported by the Dutch Epilepsy Foundation.This study provides Class III evidence that sirolimus does not significantly reduce seizure frequency in children with TSC and intractable epilepsy. The study lacked the precision to exclude a benefit from sirolimus.© 2016 American Academy of Neurology.

2016 EvidenceUpdates

133. Catamenial epilepsy: A missed cause of refractory seizure in young women (PubMed)

Catamenial epilepsy: A missed cause of refractory seizure in young women Catamenial epilepsy refers to changes in the frequency of seizures over the course of the menstrual cycle. A thorough history and detailed review of the patient's seizure diary are imperative to classify the seizures accurately and select the most appropriate antiepileptic treatment. As catamenial epilepsy rarely responds to antiepileptic medications, the physician should regularly revise the treatment plan of the women (...) with epilepsy that is refractory to the current treatment. We describe the case of a 34-year-old single woman who presented with refractory seizures.

Full Text available with Trip Pro

2016 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia

134. The experiences of people living with epilepsy in developing countries: a systematic review of qualitative evidence. (PubMed)

The experiences of people living with epilepsy in developing countries: a systematic review of qualitative evidence. Epilepsy is a global public health problem affecting people of all ages, sex, races, nations and social class. The majority of the 50 million people with epilepsy live in developing countries, with a prevalence rate of five to 10 people per 1000. The disease poses an enormous psychological, social and economic burden on patients. An estimated 90% of people with epilepsy (...) in developing countries do not receive treatment due to sociocultural, economic and political factors. Current treatment interventions are limited to the clinical management of the disease and are largely driven by the healthcare provider's perspective, ignoring the experiences of people living with epilepsy (PLWE).The aim of this review was to identify, critically appraise, extract, synthesize and present the best and most current available evidence on the experiences of PLWE in developing countries.• What

2016 JBI database of systematic reviews and implementation reports

135. Polyunsaturated fatty acid supplementation for drug-resistant epilepsy. (PubMed)

Polyunsaturated fatty acid supplementation for drug-resistant epilepsy. An estimated 1% to 3% of all individuals will receive a diagnosis of epilepsy during their lives, which corresponds to approximately 50 million affected people worldwide. The real prevalence is possibly higher because epilepsy is underreported in developing countries. Although most will achieve adequate control of their disease though the use of medication, approximately 25% to 30% of all those with epilepsy are refractory (...) to pharmacological treatment and will continue to have seizures despite the use of two or more agents in adequate dosages. Over the last decade, researchers have tested the use of polyunsaturated fatty acid (PUFA) supplements for the treatment of refractory epilepsy, with inconsistent results. There have also been some concerns about the use of omega-3 PUFA compounds because they reduce platelet aggregation and could, in theory, cause bleeding.To assess the effectiveness and tolerability of omega-3

Full Text available with Trip Pro

2016 Cochrane

136. Psychosocial aspects of epilepsy: a wider approach (PubMed)

Psychosocial aspects of epilepsy: a wider approach Epilepsy is one of the most serious neurological conditions and has an impact not only on the affected individual but also on the family and, indirectly, on the community. A global approach to the individual must take into account cognitive problems, psychiatric comorbidities and all psychosocial complications that often accompany epilepsy. We discuss psychosocial issues in epilepsy with special focus on the relationship between stigma (...) and psychiatric comorbidities. Social barriers to optimal care and health outcomes for people with epilepsy result in huge disparities, and the public health system needs to invest in awareness programmes to increase public knowledge and reduce stigma in order to minimise such disparities.J.W.S. receives research support from the Dr Marvin Weil Epilepsy Research Fund, Eisai, GlaxoSmithKline, the World Health Organization and the EU's FP7 programme, and has been consulted by, and has received fees for lectures

Full Text available with Trip Pro

2016 BJPsych open

137. Melatonin as add-on treatment for epilepsy. (PubMed)

Melatonin as add-on treatment for epilepsy. This is an updated version of the original Cochrane review published in Issue 6, 2012.Epilepsy is one of the most common chronic neurological disorders. Despite the plethora of antiepileptic drugs (AEDs) currently available, 30% of people continue having seizures. This group of people requires a more aggressive treatment, since monotherapy, the first choice scheme, fails to control seizures. Nevertheless, polytherapy often results in a number (...) the Cochrane Epilepsy Group's Specialized Register (12 January 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 12 January 2016), and MEDLINE (Ovid, 11 January 2016). We searched the bibliographies of any identified study for further references. We handsearched selected journals and conference proceedings. We applied no language restrictions. In addition, we contacted melatonin manufacturers (i.e. Nathura) and original investigators

Full Text available with Trip Pro

2016 Cochrane

138. Transcranial magnetic stimulation for the treatment of epilepsy. (PubMed)

Transcranial magnetic stimulation for the treatment of epilepsy. Epilepsy is a highly prevalent neurological condition characterized by repeated unprovoked seizures with various etiologies. Although antiepileptic medications produce clinical improvement in most individuals, nearly a third of individuals have drug-resistant epilepsy that carries significant morbidity and mortality. There remains a need for non-invasive and more effective therapies for this population. Transcranial magnetic (...) stimulation (TMS) uses electromagnetic coils to excite or inhibit neurons, with repetitive pulses at low-frequency producing an inhibitory effect that could conceivably reduce cortical excitability associated with epilepsy.To assess the evidence for the use of TMS in individuals with drug-resistant epilepsy compared with other available treatments in reducing seizure frequency, improving quality of life, reducing epileptiform discharges, antiepileptic medication use, and side-effects.We searched

Full Text available with Trip Pro

2016 Cochrane

139. Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP). (PubMed)

Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP). Sudden Unexpected Death in Epilepsy (SUDEP) is defined as sudden, unexpected, witnessed or unwitnessed, non-traumatic or non-drowning death of people with epilepsy, with or without evidence of a seizure, excluding documented status epilepticus and in whom postmortem examination does not reveal a structural or toxicological cause for death. SUDEP has a reported incidence of 1 to 2 per 1000 patient years and represents (...) the most common epilepsy-related cause of death. The presence and frequency of generalised tonic-clonic seizures (GTCS), male sex, early age of seizure onset, duration of epilepsy, and polytherapy are all predictors of risk of SUDEP. The exact pathophysiology of SUDEP is currently unknown, although GTCS-induced cardiac, respiratory, and brainstem dysfunction appears likely. Appropriately chosen antiepileptic drug treatment can render around 70% of patients free of all seizures. However, around one

Full Text available with Trip Pro

2016 Cochrane

140. Laser interstitial thermal therapy for treating intracranial lesions and epilepsy: a health technology assessment and policy analysis

Laser interstitial thermal therapy for treating intracranial lesions and epilepsy: a health technology assessment and policy analysis Laser interstitial thermal therapy for treating intracranial lesions and epilepsy: a health technology assessment and policy analysis Laser interstitial thermal therapy for treating intracranial lesions and epilepsy: a health technology assessment and policy analysis Leggett LE, Coward S, Weaver C, Sevick LK, Zhang D, Mackean G, Lorenzetti D, Clement F Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Leggett LE, Coward S, Weaver C, Sevick LK, Zhang D, Mackean G, Lorenzetti D, Clement F . Laser interstitial thermal therapy for treating intracranial lesions and epilepsy: a health technology assessment and policy analysis. Calgary: HTA Unit, University of Calgary 2016 Authors' conclusions Two studies

2016 Health Technology Assessment (HTA) Database.